39188-62-0

Basic information

• Product Name: 4-BENZYLOXYPHENYLACETYL CHLORIDE
• Synonyms: 4-BENZYLOXYPHENYLACETYL CHLORIDE;Benzyloxyphenylacetylchloride;4-BENZYLOXYPHENYLACETYL CHLORIDE 96+%;2-(4-phenylmethoxyphenyl)acetyl chloride;2-(4-(Benzyloxy)
• CAS NO: 39188-62-0
• Molecular Formula: C₁₅H₁₃ClO₂
• Molecular Weight: 260.72
• Mol File: 39188-62-0.mol
• Article Data: 19

Chemical Properties

• Melting Point: 74°C
• Appearance: /
• Solubility: soluble in Methanol,Toluene
• CAS DataBase Reference: 4-BENZYLOXYPHENYLACETYL CHLORIDE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-BENZYLOXYPHENYLACETYL CHLORIDE(39188-62-0)
• EPA Substance Registry System: 4-BENZYLOXYPHENYLACETYL CHLORIDE(39188-62-0)

Safety Data

• Statements: 34-36
• Safety Statements: 26-36/37/39
• RIDADR: 3261
• HazardClass: 8
• PackingGroup: II
• Hazardous Substances Data: 39188-62-0(Hazardous Substances Data)

Usage

General Description

4-BENZYLOXYPHENYLACETYL CHLORIDE is a chemical compound also known as benzyl 4-((4-chlorophenyl)oxymethyl)phenylacetate. It is commonly used as an intermediate in the synthesis of pharmaceuticals and organic compounds. As an acetyl chloride derivative, it is often employed in organic synthesis as a reagent for introducing the benzoyl group into other molecules. Its molecular structure consists of a phenyl ring with an acetyl chloride group attached, as well as a benzyl ether linkage. 4-BENZYLOXYPHENYLACETYL CHLORIDE is known for its use in the development of various drugs and pharmaceuticals, as well as its role in organic synthesis.

Upstream product

• 100-39-0 benzyl bromide 
• 100-44-7 benzyl chloride 
• 156-38-7 4-hydroxyphenylacetate 
• 838-96-0 2-[4-(benzyloxy)phenyl]acetonitrile 
• 6547-53-1 2-[4-(benzyloxy)benzyl]acetic acid 

Downstream Products

• 54170-03-5 (4-benzyloxy-phenyl)-acetic acid-(4-hydroxy-3-methoxy-phenethylamide) 
• 84199-13-3 4-benzyloxybenzene-acetamide 
• 58609-24-8 2-(4-(benzyloxy)phenyl)-N-(p-tolyl)acetamide 
• 151562-44-6 1,8-Dihydroxy-10-[1-oxo-2-(4-phenylmethoxyphenyl)ethyl]-9(10H)-anthracenone 
• 21882-92-8 N-[2-(3-Benzyloxy-2,4-dimethoxy-phenyl)-ethyl]-2-(4-benzyloxy-phenyl)-acetamide 
• 181268-39-3 4-{[2-(4-Benzyloxy-phenyl)-acetyl]-phenethyl-amino}-butyric acid ethyl ester 
• 202932-15-8 (4S,5R)-3-[2-(4-Benzyloxy-phenyl)-acetyl]-4-methyl-5-phenyl-oxazolidin-2-one 
• 256424-24-5 N-(3,5-dimethoxyphenyl)-2-(4-benzyloxyphenyl)acetamide 
• 855925-31-4 (4-hydroxy-phenyl)-acetic acid-(2,2-diethoxy-ethylamide) 
• 84891-45-2 diethyl (4-benzyloxy)phenylacetyl phosphonate 
• 1094489-30-1 C₅₀H₆₆N₄O₂₂ 

Relevant articles and documents

Synthetic studies toward melotenine A

Attempts to the construction of B/C ring and E ring in melotenine A are described. Based on para-dienone chemistry, a tactical application of tandem aminolysis/aza-Michael addition reaction was made to access highly functionalized building blocks with the

PdII-Catalyzed methoxylation of C(sp3)-H bonds adjacent to benzoxazoles and benzothiazoles

The Pd(OAc)2/PhI(OAc)2 catalyst system promotes the highly regioselective dehydrogenative methoxylation of a C(sp3)-H bond adjacent to benzoxazole and benzothiazole rings. The title transformation constitutes the first example of a Pd-catalyzed C(sp3)-H activating methoxylation at the proximal-selective α-position with regard to a directing auxiliary and provides expedient access to an important class of azole-decorated methyl ethers (up to 90% isolated yield). The synthetic practicality of the methodology was demonstrated by achieving α-methoxyacetic acids via the elimination of the benzoxazole auxiliaries and by obtaining the precursor of an O-methylated Breslow intermediate.

Design, synthesis, and biological evaluation of oxazolidone derivatives as highly potent N-acylethanolamine acid amidase (NAAA) inhibitors

N-Acylethanolamine-hydrolyzing acid amidase (NAAA) is a lysosomal enzyme that catalyzes the hydrolysis of endogenous fatty acid ethanolamides (FAEs), such as N-palmitoylethanolamide (PEA). PEA exhibits anti-inflammatory and analgesic activities by engaging peroxisome proliferator-activated receptor α (PPAR-α). Preventing PEA degradation by inhibition of NAAA has been proposed as a novel strategy for the treatment of inflammation and pain. In the present study, we reported the discovery of the oxazolidone derivative as a novel scaffold for NAAA inhibitors, and studied the structure-activity relationship (SAR) by modification of the side chain and terminal lipophilic substituents. The results showed that the link chain length of C5, straight and saturated linkages were the preferred shape patterns for NAAA inhibition. Several nanomolar NAAA inhibitors were described, including 2f, 3h, 3i and 3j with IC50 values of 270 nM, 150 nM, 100 nM and 190 nM, respectively. Enzymatic degradation studies suggested that 2f inhibited NAAA in a selective, noncompetitive and reversible pattern. Moreover, 2f showed high anti-inflammatory and analgesic activities after systemic and oral administration.